World Cancer Day : IRE ELiT wants to encourage the research and development of radiopharmaceuticals applications for cancer imaging

IRE ELiT, one of the two worlds producers of Gallium-68 (Ga-68) radiopharmaceutical generators, is expanding its range with a Ga-68 generator specifically designed for preclinical research of new radiopharmaceuticals. At the preclinical stage, Ga-68 generators are mainly used in oncology for PET (positron emission tomography) diagnostic imaging to determine the number and aggressiveness of tumors and metastases.

Today, radiopharmaceuticals combining a Ga-68-labelled carrier molecule are already approved and many others are in the final stages of development. Access to Ga-68 generators has fundamentally changed the management of patients suffering from neuroendocrine cancers, which are particularly difficult to detect at an early stage. The results of ongoing clinical studies give the same hope for patients with recurrent prostate cancer, thanks to more precise diagnoses.

To encourage the research and development of other radiopharmaceuticals, IRE ELiT now offers to all research players, such as hospitals, university laboratories, research centers and healthcare manufacturers, a research generator dedicated to preclinical activities, i.e. the early stages of development before human clinical trials. This generator has the same level of quality and reliability as the generator authorized for clinical activities. However, in order to meet the needs of research teams, it will offer activities lower than those required for routine examinations at more accessible prices.

IRE ELiT's line of generators is therefore expanding, since Galli RD is being added to the radiopharmaceutical generators approved in Europe and in the US, as well as the Galli Demo, a demonstration model with no activity for team training. Galli RD is rapidly available to users - within a maximum of 8 weeks - thanks to an increase in IRE ELiT's production capacity to meet the needs of the market.

IRE ELiT's Strategic Director, Jean Bonnet, said "We want to make our contribution throughout the life cycle of radiopharmaceutical products, from their discovery to clinical application, by facilitating access to Ga-68 for research teams, which testify IRE ELiT's commitment to researchers and clinicians".

Bérénice Pignol

IRE - IRE ELiT

Get updates in your mailbox

By clicking "Subscribe" I confirm I have read and agree to the Privacy Policy.

About IRE and IRE ELiT

About IRE

The Institute for Radioelements (IRE) is a public utility foundation primarily focused on producing radioisotopes for diagnostic and therapeutic applications in nuclear medicine. IRE is the global leader in Molybdenum-99 production, the parent isotope of metastable Technetium-99m, the most widely used isotope in nuclear medicine for various examinations (heart, bones, lungs, thyroid, brain, kidneys, etc.). Beyond its production activities, IRE contributes to environmental protection and monitoring through its IRE Lab division, offering services such as radioactivity measurement in various samples, radiological characterization of waste and contaminated materials, and consultancy and technical support in radiological and nuclear fields.

IRE ELiT, the innovation subsidiary founded in 2010, develops radiopharmaceuticals for cancer imaging and treatment. Together, IRE and IRE ELiT employ more than 270 people. More information: www.ire.eu

 

 

Contact

www.ire.eu